These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30010028)

  • 1. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
    Rubin J; Steidley DE; Carlsson M; Ong ML; Maurer MS
    J Card Fail; 2018 Aug; 24(8):504-511. PubMed ID: 30010028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis.
    Tendler A; Helmke S; Teruya S; Alvarez J; Maurer MS
    Amyloid; 2015 Mar; 22(1):61-6. PubMed ID: 25510353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
    Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of the Myocardial Contraction Fraction, as Calculated from M-Mode Echocardiography, With Incident Heart Failure, Atherosclerotic Cardiovascular Disease and Mortality (Results from the Cardiovascular Health Study).
    Maurer MS; Koh WJ; Bartz TM; Vullaganti S; Barasch E; Gardin JM; Gottdiener JS; Psaty BM; Kizer JR
    Am J Cardiol; 2017 Mar; 119(6):923-928. PubMed ID: 28073429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images-reference values and performance in patients with heart failure and left ventricular hypertrophy.
    Arenja N; Fritz T; Andre F; Riffel JH; Aus dem Siepen F; Ochs M; Paffhausen J; Hegenbart U; Schönland S; Müller-Hennessen M; Giannitsis E; Kristen AV; Katus HA; Friedrich MG; Buss SJ
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1414-1422. PubMed ID: 28165128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
    Castaño A; Narotsky DL; Hamid N; Khalique OK; Morgenstern R; DeLuca A; Rubin J; Chiuzan C; Nazif T; Vahl T; George I; Kodali S; Leon MB; Hahn R; Bokhari S; Maurer MS
    Eur Heart J; 2017 Oct; 38(38):2879-2887. PubMed ID: 29019612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
    Bhuiyan T; Helmke S; Patel AR; Ruberg FL; Packman J; Cheung K; Grogan D; Maurer MS
    Circ Heart Fail; 2011 Mar; 4(2):121-8. PubMed ID: 21191093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World Data.
    Müller ML; Latinova E; Brand A; Mattig I; Spethmann S; Messroghli D; Hahn K; Landmesser U; Heidecker B
    J Am Heart Assoc; 2024 Jul; 13(14):e033478. PubMed ID: 38958150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.
    Hanson JLS; Arvanitis M; Koch CM; Berk JL; Ruberg FL; Prokaeva T; Connors LH
    Circ Heart Fail; 2018 Feb; 11(2):e004000. PubMed ID: 29449366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype.
    Singulane C; Sun D; Hu Z; Lee L; Sarswat N; Emami Neyestanak M; Patel AR; Lang RM; Addetia K
    Curr Probl Cardiol; 2024 Sep; 49(9):102729. PubMed ID: 38945183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.